After hours: 4:34PM EDT
|Bid||41.16 x 3000|
|Ask||42.58 x 800|
|Day's Range||41.62 - 42.40|
|52 Week Range||31.56 - 42.40|
|Beta (3Y Monthly)||0.66|
|PE Ratio (TTM)||32.70|
|Earnings Date||Jul 23, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||43.66|
NEW YORK, NY / ACCESSWIRE / June 20, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 24, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) investors who purchased securities between February 26, 2015 and April 16, 2019, inclusive (the “Class Period”).
Boston Scientific Corporation (NYSE:BSX), a large-cap worth US$58b, comes to mind for investors seeking a strong and...
NEW YORK, NY / ACCESSWIRE / June 19, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have ...
NEW YORK, June 19, 2019 -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Sprint Corporation,.
NEW YORK, NY / ACCESSWIRE / June 19, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review ...
Boston Scientific Corp NYSE:BSXView full report here! Summary * Perception of the company's creditworthiness is neutral * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for BSX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BSX. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding BSX are favorable, with net inflows of $9.25 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NeutralThe current level displays a neutral indicator. BSX credit default swap spreads are near their highest levels of the last 3 years, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
NEW YORK, NY / ACCESSWIRE / June 17, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have ...
NEW YORK, NY / ACCESSWIRE / June 17, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review ...
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Boston Scientific Corporation (“Boston Scientific” or “the Company”) (NYSE: BSX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. You can also reach us through the firm's website at www.schallfirm.com, or by email at firstname.lastname@example.org.
NEW YORK, June 17, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
All eyes are on the US Federal Reserve right now. On Wednesday, the Fed will reveal whether it decides to slash interest rates or keep them steady at 2.25% - 2.50%. Ahead of the announcement, the general consensus is that the Fed will keep rates steady but set the groundwork for cuts when it next meets in July. “The markets are set up for a cut in July, and if they don’t get it, financial conditions will tighten” Carl Tannenbaum, chief economist at Northern Trust, told Reuters.So how should investors prepare their portfolios going forward? Goldman Sachs has some advice. “If the Fed does cut rates, the S&P 500 usually rallies afterward, with health care and consumer staples outperforming and information technology consistently lagging,” Goldman's chief U.S. equity strategist David Kostin said. The “communication services sector has generated the best relative returns and hit rate of outperformance during the subsequent 3 months (+4 pp, 100%), but has underperformed over a 12-month horizon.”Here we take a closer look at three stocks that fit into these two categories, with 2 healthcare stocks and 1 consumer staples stock. What’s more, all three of these stocks show a ‘Strong Buy’ Street consensus. That’s based on all ratings received over the last three months. Let’s take a closer look at why analysts are so bullish on these stocks now: 1\. Boston Scientific (BSX)Boston Scientific manufactures medical devices used in interventional medical specialties, including everything from needles to pacemakers. Shares are up 14% year-to-date, and over 80% on a three-year basis. Right now, the company is gearing up for its investor day on June 26. This is the first event since 2017- and expectations are high that BSX met or exceeded all of the 2017 and 2018 financial targets. Needham analyst Mike Matson is confident that BSX can sustain high single digit growth over the next few years, and expects it to target organic revenue growth of 7-9% from 2019 to 2022 at the event. “Given BSX’s strong fundamentals (durable high single digit revenue growth, diversified product portfolio, margin expansion potential, etc.), we believe there is potential for upside to consensus estimates and additional multiple expansion and we reiterate our Strong Buy rating” writes Matson. He reiterated his BSX ‘Buy’ rating on June 14 with a $46 price target (14% upside potential). As we can see here the stock has received 9 recent buy ratings and 1 hold rating:View BSX Price Target & Analyst Ratings Detail 2\. Medtronic (MDT)Ireland-based Medtronic is one of the world’s largest medical device makers. Although the company manufactures a wide range of products, most of the hype right now is centered on the MazorX robotic platform. Medtronic snapped up Mazor Robotics for $1.7 billion late last year, and the two companies have now developed the MazorX Stealth Edition robotic guidance platform. The power of the platform is a preoperative planning suite with 3D analytics and tools, which allows surgeons to optimize the surgical process in advance. “Part of MDT’s revenue acceleration thesis depends on the success of MazorX in driving spine share gains” writes Evercore ISI analyst Vijay Kumar. He recently reiterated his Medtronic Buy rating with a $108 price target. “We think MDT’s view of ‘several hundred bps of share gains’ in spine remains a credible thesis given early trends we are seeing. Extrapolating these to general surgery (~80% systems placed for committed implant / consumable volume) lends further credence to why we think robotic surgery could be a big deal for MDT” writes Kumar. The analyst concludes: “We think MDT is the perfect stock for a choppy environment, and should be a core holding given this revenue reacceleration thesis.” That’s alongside Wells Fargo analyst Larry Biegelsen upgrading Medtronic from Hold to Buy with a $110 price target. The analyst comments "We believe MDT is an accelerating growth story trading at a steep discount to its peers."Overall 7 analysts have published buy ratings on MDT in the last three months, with just 2 analysts staying sidelined.View MDT Price Target & Analyst Ratings Detail 3\. Tyson Foods (TSN)While many investors are pouring money into Beyond Foods, it’s also worth taking a closer look at Tyson Foods. This is the world's second largest processor and marketer of chicken, beef, and pork. However the company has also recently branched out into plant-based meat alternatives, including chicken nuggets and patties. Shares have rocketed with a 53% gain so far year-to-date. Boosting prices further was a rating upgrade from Argus Research’s John Staszak. He has a $92 price target on TSN (12% upside potential).Staszak cited a “growing demand for proteins" and notes that Tyson's beef division is experiencing "especially strong demand". Plus the company is working hard to increase prepared foods sales to satisfy the "steady demand and strong margins." And to top of it, Tyson trades at a multiple of just 12.8-times forward earnings, which is below the average large-cap food processor multiple of 18.4-times. It’s also easily towards the low end of Tyson’s own historical 9- to 19-times range. The stock boasts 7 recent bullish calls, with only 1 analyst publishing a Sell rating (Pivotal Research's Timothy Ramey). View TSN Price Target & Analyst Ratings Detail Discover stock ideas from the Street’s best performing analysts here
NEW YORK, June 14, 2019 -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Indivior PLC, Boston.
A nonsurgical method of heart-valve replacement, dubbed TAVR, is gaining steam in the U.S. — propping up medical technology companies Edwards and Medtronic, an analyst said Friday.
NEW YORK, NY / ACCESSWIRE / June 14, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have ...
NEW YORK, June 14, 2019 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following.
CEDARHURST, NY / ACCESSWIRE / June 14, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.
NEW YORK, NY / ACCESSWIRE / June 14, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review ...
On its first-quarter earnings conference call, Boston Scientific (BSX) reaffirmed its 2019 organic revenue growth guidance in the high-single-digit range. However, the company has also highlighted the low probability of beating or delivering at the high end of its organic revenue growth guidance.
NEW YORK, NY / ACCESSWIRE / June 13, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have ...
NEW YORK, NY / ACCESSWIRE / June 12, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...
NEW YORK, June 12, 2019 -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation (“Boston Scientific” or the “Company”).
Boston Scientific (BSX) is pulling out all the stops to strengthen its core businesses as well as invest in new technologies and the overseas markets.